Pollack H, Zhan M X, Moore T, Tao P Z, Krasinski K, Borkowsky W
Department of Pediatrics, New York University Medical Center, NY 10016.
J Infect Dis. 1994 Oct;170(4):1003-6. doi: 10.1093/infdis/170.4.1003.
The effect of zidovudine therapy on human immunodeficiency virus (HIV)-specific antibody production was studied in 64 HIV-1-infected infants and children > 6 months old. HIV-specific in vitro antibody production (IVAP) was measured in cultures of peripheral blood mononuclear cells (PBMC). IVAP decreased in 85% of children after zidovudine was initiated (mean decline, 1 log within 2 months). Effects were seen as early as 1 week after starting zidovudine. No change in IVAP was seen in children not treated. In comparison, plasma core (p24) antigen levels declined and CD4+ lymphocytes increased in only 42% and 52%, respectively, of treated subjects. Thus, the production of antibody to HIV-1 decreases rapidly after the initiation of antiretroviral therapy. This response to therapy may provide a simple and sensitive method of monitoring antiretroviral therapy.
在64名年龄大于6个月的感染人类免疫缺陷病毒（HIV）的婴幼儿中，研究了齐多夫定治疗对HIV特异性抗体产生的影响。通过外周血单个核细胞（PBMC）培养来检测HIV特异性体外抗体产生（IVAP）。开始使用齐多夫定后，85%的儿童IVAP下降（平均下降，2个月内1个对数级）。在开始使用齐多夫定后1周就可见到效果。未接受治疗的儿童IVAP未见变化。相比之下，接受治疗的受试者中，血浆核心（p24）抗原水平仅在42%的受试者中下降，CD4+淋巴细胞仅在52%的受试者中增加。因此，抗逆转录病毒治疗开始后，HIV-1抗体的产生迅速减少。这种对治疗的反应可能为监测抗逆转录病毒治疗提供一种简单而敏感的方法。
